ArticleScientific reports2025
Identification of IL1R1 as a potential key PANoptosis-related gene in myocardial ischemia-reperfusion injury using machine learning.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PANoptosis nexus in ischemia-reperfusion injury: from integrated cell death mechanisms to novel therapeutic opportunities.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial ischemia-reperfusion injury (MIRI) involves multifaceted pathogenic mechanisms, including inflammatory responses, immune dysregulation, and emerging forms of programmed cell death such as PANoptosis. However, the precise regulatory genes linking PANoptosis to MIRI remain largely unexplored. Transcriptomic data from public MIRI datasets were analyzed to identify PANoptosis-related genes. Key genes were screened via univariate logistic regression and three machine learning algorithms (LASSO, SVM-RFE, and Random Forest). The top candidate was evaluated through ROC analysis, GSEA, immune infiltration profiling, and drug prediction. Experimental validation was performed using both OGD/R cell models and a murine MIRI mode. Five DPRGs were identified, of which IL1R1 was consistently selected as a key PRG (KPRG) across all three machine learning methods. ROC analysis demonstrated a high diagnostic performance for IL1R1 (AUC = 0.956). IL1R1 was enriched in MAPK and ECM-receptor pathways and negatively correlated with CD8 + T cell infiltration. Molecular docking suggested IL1R1 could be targeted by cardioprotective drugs such as Atorvastatin and Pioglitazone. In both the OGD/R model and murine MIRI model, IL1R1 and p-P65 expression were significantly upregulated, supporting the activation of the IL1R1/p-P65 axis. Notably, siRNA-mediated IL1R1 knockdown suppressed P65 expression, indicating that inhibition of the IL1R1/p-P65 axis may mitigate PANoptosis. This study suggests that IL1R1 may play a role in PANoptosis during myocardial ischemia-reperfusion injury. Based on bioinformatics, machine learning, and preliminary experimental validation, IL1R1 could be a potential biomarker or therapeutic target, although further research is needed to confirm its clinical significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.